NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Trevi Therapeutics, Inc. (TRVI) Stock Analysis

Trevi Therapeutics, Inc. (TRVI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TRVI

$17.26

+$0.20 (+1.17%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TRVI with… →

TRVI Key Statistics

As of Sep 4, 2026
Trading
Open
$16.88
Previous Close
$17.06
Day's Range
16.80–17.32
52-Week Range
6.98–20.22
Volume
856.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.05
Valuation
Market Cap
$2.46B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.35
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$42.76M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
142.48M
1-Year Return
+138.73%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
2.18M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TRVI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+37.86%
2025+203.88%
2024+207.46%
2023−30.57%
2022+146.80%
2021−67.69%
2020−35.47%
2019 (partial year)−52.47%

As of September 4, 2026.

TRVI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$42.76M—
2024$0.00−$47.91M—
2023$0.00−$29.07M—
2022$0.00−$29.15M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$49.33M−$42.76M—
2024$0.00—−$51.52M−$47.91M—
2023$0.00—−$33.92M−$29.07M—
2022$0.00—−$29.91M−$29.15M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TRVI Valuation vs Biotechnology Median

Median of 656 stocks
MetricTRVIBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Trevi Therapeutics, Inc. (TRVI) is capitalised at $2.46B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 34.

Over the past 52 weeks the price has ranged from $6.98 to $20.22. The most recent close on file for TRVI is $17.26, dated September 4, 2026. That is +$0.20 (+1.17%) against the previous close. The latest close sits 147.28% above that 52-week low.

Financial Health

In fiscal 2025, Trevi Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $42.76M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.35.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +138.73%. Measured over 5 years, that is +60.91% a year compounded. The reported beta is 1.05. Daily returns over the trailing 7 years annualize to a volatility of 98.54%.

Growth & Income

The record shows no dividend for TRVI.

2026 is still running; the price is +37.86% year to date. Across the complete calendar years on file, 2024 returned +207.46% and 2021 returned −67.69%. Of the 6 complete calendar years on file, 3 finished higher.

Peer Comparison

Trevi Therapeutics, Inc. (TRVI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Trevi Therapeutics, Inc. TRVI $2.46B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Trevi Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Visit website →